A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor
Open accessThe DOI matches its Crossref record; 95 of the 95 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The neurochemical and biological effects of antidepressant medications have become better defined over the last decade. When the anti-depressant bupropion was introduced in the United States in 1989, the specific pharmacologic basis of its clinical effects was uncertain. Research conducted over the past decade has significantly advanced the understanding of the neuropharmacology of bupropion and has demonstrated a novel mechanism of antidepressant activity. This article discusses the mechanism of action of bupropion and relates the drug's neuropharmacologic effects to its clinical efficacy and tolerability profiles. DATA SOURCES: Data were obtained via the MEDLINE database in an English-language search spanning the period 1965 to May 2002 and using the search terms bupropion, bupropion SR, and antidepressants, as well as from the manufacturer's bupropion databases. CONCLUSIONS: The preclinical and clinical data show that bupropion acts via dual inhibition of norepinephrine and dopamine reuptake and is devoid of clinically significant serotonergic effects or direct effects on postsynaptic receptors. Dual norepinephrine and dopamine reuptake inhibition is associated with a unique clinical profile. Bupropion has demonstrated efficacy comparable to that of other antidepressants. However, because bupropion is a selective norepinephrine and dopamine reuptake inhibitor with no serotonergic activity, common antidepressant-associated side effects, such as sexual dysfunction, weight gain, and sedation, are not associated with bupropion therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Bupropion is a second-generation AD that acts as a selective inhibitor of catecholamines' (noradrenaline and dopamine) reuptake, devoid of any serotonergic; antihistamine; or anticholinergic properties (Stahl et al., 2004).”
From Is There a Potential of Misuse for Venlafaxine and Bupropion? (2018) · cites this paper as Stahl et al., 2004
In the citing paper
“Inhibition of catecholamine reuptake is one of bupropion’s mechanisms of action [215].”
From Mechanistic insights into nicotine withdrawal (2011) · cites this paper as [215]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Selective serotonin reuptake inhibitors (SSRIs) versus other antidepressants for depression
Geddes, J. R., Freemantle, N., Mason, J. M., Eccles, M., & Boynton, J. R. (1999) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001851 · Cited by 125
RetractedGoodman & Gilman's The Pharmacological Basis of Therapeutics
Brunton, L. L. (1985) · Cited by 7,321
Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants
Santarelli, L., Saxe, M., Gross, C., Surget, A., Battaglia, F., Dulawa, S., Weisstaub, N., Lee, J., Duman, R., Arancio, O., et al. (2003) · Science · doi:10.1126/science.1083328 · Cited by 4,321
The cellular neurobiology of depression
Manji, H. K., Drevets, W. C., & Charney, D. S. (2001) · Nature Medicine · doi:10.1038/87865 · Cited by 1,182 · cited 1×
“cause depression and modulate responses to antidepressants.(14,16,19) Several observations support an “upstream””
BackgroundUntreated Depression and Hippocampal Volume Loss
Sheline, Y. I., Gado, M. H., & Kraemer, H. C. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.8.1516 · Cited by 1,180 · cited 1×
“Antidepressants may thus play a neuroprotective role, a possibility supported by observations that hippocampal neurogenesis may be required for the behavior effects of antidepressants in mice(23) and that progressive loss of hippocampal volume occurs during chronically untreated depression in humans.(24,25)”
BackgroundPharmacological profile of antidepressants and related compounds at human monoamine transporters
Tatsumi, M., Groshan, K., Blakely, R. D., & Richelson, E. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)01393-9 · Cited by 939 · cited 1×
“For example, antidepressants differ by more than 1000fold in potency at inhibiting monoamine reuptake, yet their efficacies are comparable and seemingly unrelated to potency.(21) Third, although all antidepressants enhance monoaminergic neurotransmission, they do so via disparate mechanisms, consistent with the possib…”
Background(2000) · PubMed · Cited by 685
Bupropion: a review of its mechanism of antidepressant activity.
Ascher, J. A., Cole, J. O., Colin, J. N., Feighner, J. P., Ferris, R. M., Fibiger, H. C., Golden, R. N., Martin, P., Potter, W. Z., & Richelson, E. (1995) · PubMed · Cited by 680
Prevalence of Sexual Dysfunction Among Newer Antidepressants
Clayton, A. H., Pradko, J. F., Croft, H. A., Montano, C. B., Leadbetter, R. A., Bolden-Watson, C., Bass, K. I., Donahue, R. M. J., Jamerson, B. D., & Metz, A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0414 · Cited by 542
Self-citationThe Expert Consensus Guideline Series: Medication Treatment of Bipolar Disorder 2000.
Sachs, G. S., PRINTZ, D. J., Kahn, D. A., Carpenter, D. P., & Docherty, J. P. (2000) · PubMed · Cited by 534
Effects of Psychotropic Drugs on Seizure Threshold
Pisani, F., Oteri, G., Costa, C., Di Raimondo, G., & Di Perri, R. (2002) · Drug Safety · doi:10.2165/00002018-200225020-00004 · Cited by 352 · cited 1×
“1%.(107,108) For bupropion, the incidence of seizure reported in the product information for the older, immediate-release formulation (Wellbutrin) is 0.”
BackgroundBupropion Hydrochloride in Attention Deficit Disorder with Hyperactivity
CONNERS, C. K., CASAT, C. D., GUALTIERI, C. T., WELLER, E., READER, M., REISS, A., WELLER, R. A., KHAYRALLAH, M., & ASCHER, J. (1996) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199610000-00018 · Cited by 342
Antidepressant-Induced Sexual Dysfunction
Gregorian, R. S., Golden, K. A., Bahce, A., Goodman, C., Kwong, W. J., & Khan, Z. M. (2002) · Annals of Pharmacotherapy · doi:10.1345/aph.1a195 · Cited by 320
Bupropion SR Enhances Weight Loss: A 48‐Week Double‐Blind, Placebo‐ Controlled Trial
Anderson, J. W., Greenway, F. L., Fujioka, K., Gadde, K. M., McKenney, J., & O'Neil, P. M. (2002) · Obesity Research · doi:10.1038/oby.2002.86 · Cited by 315 · cited 1×
“cacy as an adjunct for weight loss in nondepressed, obese individuals.(95,96) The mechanism of the weight-reducing”
BackgroundA double-blind trial of bupropion versus desipramine for bipolar depression.
Sachs, G. S., Lafer, B., Stoll, A. L., Banov, M. D., Thibault, A., Tohen, M. F., & Rosenbaum, J. F. (1994) · PubMed · Cited by 272
Pharmacology of Antidepressants—Characteristics of the Ideal Drug
RICHELSON, E. (1994) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(12)61375-5 · Cited by 257 · cited 1×
“for several weeks, most side effects occur within hours to days of initiation of an antidepressant.(73) This observation”
BackgroundStahl, S. M. (1998) · PubMed · Cited by 256
Self-citationBupropion versus Methylphenidate in the Treatment of Attention-Deficit Hyperactivity Disorder
BARRICKMAN, L. L., PERRY, P. J., ALLEN, A. J., KUPERMAN, S., ARNDT, S. V., HERRMANN, K. J., & SCHUMACHER, E. (1995) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199505000-00017 · Cited by 254
Croft, H., Settle, E., Houser, T., Batey, S. R., Donahue, R. M. J., & Ascher, J. A. (1999) · Clinical Therapeutics · doi:10.1016/s0149-2918(00)88317-4 · Cited by 242
Compositional Lineation and Its Relation to Complex Folding
Newhouse, W. H. (1955) · Science · doi:10.1126/science.122.3163.284-a · Cited by 232 · cited 1×
“This hypothesis arose from observations that the administration of classical antidepressants increased monoaminergic function, whereas monoamine depleters such as reserpine precipitated depressive symptoms in susceptible individuals.(10,11) A large body of evidence from animal models and clinical studies in depressed…”
BackgroundCompositional Lineation and Its Relation to Complex Folding
Newhouse, W. H. (1955) · Science · doi:10.1126/science.122.3163.284.a · Cited by 226
Clayton, A. H., Warnock, J. K., Kornstein, S. G., Pinkerton, R., Sheldon-Keller, A., & McGarvey, E. L. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0110 · Cited by 222 · cited 1×
“In addition, bupropion has been successfully substituted for other antidepressants that cause sexual dysfunction(83,84) and has been effective as an antidote for sexual dysfunction caused by other antidepressants in numerous uncontrolled studies and in 2 of 3 placebo-controlled clinical trials.(51,52,57) Adjunctive bu…”
BackgroundSeizures associated with antidepressants: a review.
Rosenstein, D. L., Nelson, J. C., & Jacobs, S. (1993) · PubMed · Cited by 214
Essential Psychopharmacology: The Prescriber's Guide
Naussbaum, D. (2006) · Journal of Developmental & Behavioral Pediatrics · doi:10.1097/00004703-200602000-00014 · Cited by 213
Cooper, B. R., Hester, T. J., & Maxwell, R. A. (1980) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)32266-4 · Cited by 213 · cited 1×
“antidepressant effects of bupropion and its metabolite hydroxybupropion in animal models of depression.(30) These preclinical data indicate that the mechanism of action of bupropion most likely involves its dual-reuptake inhibition of dopamine and norepinephrine (Figure 1).”
BackgroundBupropion SR vs. Placebo for Weight Loss in Obese Patients with Depressive Symptoms
Jain, A. K., Kaplan, R. A., Gadde, K. M., Wadden, T. A., Allison, D. B., Brewer, E. R., Leadbetter, R. A., Richard, N., Haight, B., Jamerson, B. D., et al. (2002) · Obesity Research · doi:10.1038/oby.2002.142 · Cited by 205
Self-citationAre SSRIs better than TCAs? Comparison of SSRIs and TCAs: A meta-analysis
Steffens, D. C., Krishnan, K. R. R., & Helms, M. J. (1997) · Depression and Anxiety · doi:10.1002/(sici)1520-6394(1997)6:1<10::aid-da2>3.0.co;2-9 · Cited by 192 · cited 1×
“and is reflected in the positions of the American Psychiatric Association,(36,37) reviewers for the Cochrane Library,(38) and clinical experts publishing independently of these organizations.(39,40) Though bupropion is distinguished from other antidepressants by its pharmacology, multiple headto-head trials comparing…”
BackgroundComparative sexual side effects of bupropion, fluoxetine, paroxetine, and sertraline*
Modell, J. G., Katholi, C. R., Modell, J. D., & DePalma, R. L. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90198-3 · Cited by 183
Self-citationHorst, W. D., & Preskorn, S. H. (1998) · Journal of Affective Disorders · doi:10.1016/s0165-0327(98)00222-5 · Cited by 182 · cited 1×
“Clinical data demonstrate that specific neurotransmitter effects are associated with distinct side effect profiles (Table 3).(17,18,20,74,75) Antidepressant-induced side effects are attributed to drug activity at central or peripheral synapses where agents either bind to neurotransmitter receptors and influence cellul…”
BackgroundColeman, C. (2001) · Clinical Therapeutics · doi:10.1016/s0149-2918(01)80090-4 · Cited by 179
The Dexamethasone Suppression Test in Patients With Mood Disorders
Rush, A. J., Giles, D. E., Schlesser, M. A., Orsulak, P. J., Parker, C. R., Weissenburger, J. E., Crowley, G. T., Khatami, M., & Vasavada, N. (1996) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v57n1006 · Cited by 174
Berken, G. H., Weinstein, D. O., & Stern, W. C. (1984) · Journal of Affective Disorders · doi:10.1016/0165-0327(84)90031-4 · Cited by 169
Changes in Weight During a 1-Year Trial of Fluoxetine
Michelson, D., Amsterdam, J. D., Quitkin, F. M., Reimherr, F. W., Rosenbaum, J. F., Zajecka, J., Sundell, K. L., Kim, Y., & Beasley, C. M. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.8.1170 · Cited by 167 · cited 1×
“With respect to SSRIs, evidence suggests weight gain may occur during long-term treatment (possibly via a serotonergic mechanism such as down-regulation of 5-HT2C receptors, although antihistaminergic effects may also contribute).(90,91) In contrast, bupropion has not been associated with weight gain.”
BackgroundBodkin, J. A., Lasser, R. A., Wines, J. D., Gardner, D. M., & Baldessarini, R. J. (1997) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v58n0401 · Cited by 159
Li, S. X.-M., Perry, K. W., & Wong, D. T. (2002) · Neuropharmacology · doi:10.1016/s0028-3908(01)00160-5 · Cited by 156
Bupropion as an Antidote for Serotonin Reuptake Inhibitor-Induced Sexual Dysfunction
Ashton, A. K., & Rosen, R. C. (1998) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v59n0304 · Cited by 155 · cited 1×
“Prim Care Companion J Clin Psychiatry 2004;6(4) 165 doses rather than occasional as-needed use.(50) In the trial in which bupropion was not effective as an antidote,(57) it is possible that an inadequate dose of bupropion was used and/or that the sexual functioning rating scale used (the Arizona Sexual Experience Scal…”
MethodNeumeister, A., Turner, E. H., Matthews, J. R., Postolache, T. T., Barnett, R. L., Rauh, M., Vetticad, R. G., Kasper, S. F., & Rosenthal, N. E. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.6.524 · Cited by 152
Bupropion Sustained Release Versus Paroxetine for the Treatment of Depression in the Elderly
Weihs, K. L., Settle, E. C., Batey, S. R., Houser, T. L., Donahue, R. M. J., & Ascher, J. A. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n0309 · Cited by 150
Double-Blind Comparison of Bupropion Sustained Release and Sertraline in Depressed Outpatients
Kavoussi, R. J., Segraves, R. T., Hughes, A. R., Ascher, J. A., & Johnston, J. A. (1997) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v58n1204 · Cited by 149
Comparison of compliance between serotonin reuptake inhibitors and tricyclic antidepressants
Montgomery, S. A., & Kasper, S. F. (1995) · International Clinical Psychopharmacology · doi:10.1097/00004850-199501004-00005 · Cited by 143 · cited 1×
“and is reflected in the positions of the American Psychiatric Association,(36,37) reviewers for the Cochrane Library,(38) and clinical experts publishing independently of these organizations.(39,40) Though bupropion is distinguished from other antidepressants by its pharmacology, multiple headto-head trials comparing…”
BackgroundBupropion and amitriptyline in the treatment of depressed patients.
LADER, M. H. (1983) · PubMed · Cited by 142
Feinsod, M., Kreinin, B., Chistyakov, A. V., & Klein, E. (1998) · Depression and Anxiety · doi:10.1002/(sici)1520-6394(1998)7:2<73::aid-da4>3.0.co;2-6 · Cited by 140
Learned-Coughlin, S. M., Bergström, M., Savitcheva, I., Ascher, J., Schmith, V. D., & Långstrom, B. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01834-6 · Cited by 138 · cited 1×
“Adapted with permission from Learned-Coughlin et al.(32) Abbreviations: (11)C-βCIT-FE = (11)C-labeled N-ω-fluoroalkyl-2βcarboxy-3-β-(4-iodophenyl) nortropane ester, SR = sustained release.”
MethodCombining Bupropion SR With Venlafaxine, Paroxetine, or Fluoxetine
Kennedy, S. H., McCann, S., Masellis, M., McIntyre, R. S., Raskin, J., McKay, G., & Baker, G. B. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0302 · Cited by 135
Modulation of feeding by hypothalamic paraventricular nucleus α1- and α2-adrenergic receptors
Wellman, P. J., Davies, B. T., Morien, A., & McMahon, L. R. (1993) · Life Sciences · doi:10.1016/0024-3205(93)90243-v · Cited by 135
Coleman, C. C., Cunningham, L. A., Foster, V. J., Batey, S. R., Donahue, R. M. J., Houser, T. L., & Ascher, J. A. (1999) · Annals of Clinical Psychiatry · doi:10.1023/a:1022309428886 · Cited by 133
Improvement in fluoxetine-associated sexual dysfunction in patients switched to bupropion.
Walker, P. W., Cole, J. O., Gardner, E. A., Hughes, A. R., Johnston, J. A., Batey, S. R., & Lineberry, C. G. (1993) · PubMed · Cited by 132
Nomikos, G. G. (1989) · Neuropsychopharmacology · doi:10.1016/0893-133x(89)90031-6 · Cited by 130
Studies of bupropion's mechanism of antidepressant activity.
Ferris, R. M., Cooper, B. R., & Maxwell, R. A. (1983) · PubMed · Cited by 129
Efficacy and Tolerability of Paroxetine for the Long-Term Treatment of Generalized Anxiety Disorder
Stocchi, F., Nordera, G., Jokinen, R., Lepola, U. M., Hewett, K., Bryson, H., Iyengar, M. K., & Paroxetine Generalized Anxiety Disorder Study Team (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0305 · Cited by 128
Treatment of depression--newer pharmacotherapies.
Mulrow, C. D., Williams, J. W., Trivedi, M. H., Chiquette, E., Aguilar, C., Cornell, J. E., Badgett, R. G., Noël, P. H., Lawrence, V. A., Lee, S., et al. (1999) · PubMed Central · Cited by 124
Bupropion occupancy of the dopamine transporter is low during clinical treatment
Meyer, J. H., Goulding, V. S., Wilson, A. A., Hussey, D., Christensen, B. K., & Houle, S. (2002) · Psychopharmacology · doi:10.1007/s00213-002-1166-3 · Cited by 122
Antidepressant Drugs and Seizure Susceptibility: From In Vitro Data to Clinical Practice
Pisani, F., Spina, E., & Oteri, G. (1999) · Epilepsia · doi:10.1111/j.1528-1157.1999.tb00885.x · Cited by 122 · cited 1×
“1%.(107,108) For bupropion, the incidence of seizure reported in the product information for the older, immediate-release formulation (Wellbutrin) is 0.”
BackgroundSynaptic Effects of Antidepressants
RICHELSON, E. (1996) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199606002-00001 · Cited by 120 · cited 2×
“Clinical data demonstrate that specific neurotransmitter effects are associated with distinct side effect profiles (Table 3).(17,18,20,74,75) Antidepressant-induced side effects are attributed to drug activity at central or peripheral synapses where agents either bind to neurotransmitter receptors and influence cellul…”
BackgroundWeight Gain with Antidepressants and Lithium
Garland, E., Remick, R. A., & Zis, A. P. (1988) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198810000-00003 · Cited by 119
Sexual side effects of antidepressants.
Rothschild, A. J. (2000) · PubMed · Cited by 117
The Pharmacologic Management of SSRI-Induced Side Effects: A Survey of Psychiatrists
Dording, C., Mischoulon, D., Petersen, T., Kornbluh, R., Gordon, J., Nierenberg, A., Rosenbaum, J., & Fava, M. (2002) · Annals of Clinical Psychiatry · doi:10.3109/10401230209147450 · Cited by 109
Nomikos, G. G., Damsma, G., Wenkstern, D., & Fibiger, H. C. (1992) · PubMed · Cited by 109
Comparison of Bupropion and Trazodone for the Treatment of Major Depression
Weisler, R. H., Johnston, J., Lineberry, C. G., Samara, B., Branconnier, R. J., & Billow, A. A. (1994) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199406000-00004 · Cited by 107
Masand, P. S., Ashton, A. K., Gupta, S., & Frank, B. L. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.5.805 · Cited by 100
Involvement of Serotonin and Dopamine in the Mechanism of Action of Novel Antidepressant Drugs
Bonhomme, N., & Esposito, E. (1998) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199812000-00005 · Cited by 99
Bupropion as a promising approach to rapid cycling bipolar II patients.
Haykal, R. F., & Akiskal, H. S. (1990) · PubMed · Cited by 95
Pharmacokinetic Optimisation of Sustained-Release Bupropion for Smoking Cessation
Johnston, A. J., Ascher, J. A., Leadbetter, R. A., Schmith, V. D., Patel, D. K., Durcan, M. J., & Bentley, B. (2002) · Drugs · doi:10.2165/00003495-200262002-00002 · Cited by 95
CRF/NPY interactions: A potential role in sleep dysregulation in depression and anxiety
Ehlers, C. L., Somes, C., Seifritz, E., & Rivier, J. E. (1997) · Depression and Anxiety · doi:10.1002/(sici)1520-6394(1997)6:1<40::aid-da6>3.0.co;2-9 · Cited by 91
Wilens, T. E., Prince, J. B., Spencer, T. J., Patten, S. L. V., Doyle, R., Girard, K., Hammerness, P. G., Goldman, S., Brown, S., & Biederman, J. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01664-5 · Cited by 91 · cited 1×
“inducing mania may be related to its absence of serotonergic properties or effects on postsynaptic β-receptors.(71,72) In”
BackgroundSegraves, R. T., Kavoussi, R. J., Hughes, A. R., Batey, S. R., Johnston, J. A., Donahue, R. M. J., & Ascher, J. A. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200004000-00002 · Cited by 91
Selecting an antidepressant by using mechanism of action to enhance efficacy and avoid side effects.
Stahl, S. M. (1998) · PubMed · Cited by 85
Self-citationDeBattista, C., Solvason, H. B., Poirier, J., Kendrick, E., & Schatzberg, A. F. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200302000-00005 · Cited by 83
Substitution of an SSRI With Bupropion Sustained Release Following SSRI-Induced Sexual Dysfunction
Clayton, A. H., McGarvey, E. L., Abouesh, A., & Pinkerton, R. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n0309 · Cited by 83
Safety profile of sustained-release bupropion in depression: Results of three clinical trials
Settle, E. C., Stahl, S. M., Batey, S. R., Johnston, J. A., & Ascher, J. A. (1999) · Clinical Therapeutics · doi:10.1016/s0149-2918(00)88301-0 · Cited by 83 · cited 2×
“controlled clinical trials of bupropion did not differ between bupropion SR and placebo.(76) In addition, in a pooled analysis(41) of all studies comparing bupropion with”
BackgroundResultSelf-citationDEPRESSION AND ANXIETY DISORDERS
Brown, C. (2001) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/s0889-8545(05)70199-6 · Cited by 81
Croft, H. A., Houser, T. L., Jamerson, B. D., Leadbetter, R. A., Watson, C. B., Donahue, R. M. J., & Metz, A. L. (2002) · Clinical Therapeutics · doi:10.1016/s0149-2918(02)85141-4 · Cited by 79
Golden, R. N. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800260047006 · Cited by 78
Untreated Depression and Hippocampal Volume Loss
Carroll, B. J. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.7.1309-a · Cited by 78
Antidepressant-induced weight gain: A comparison study of four medications
Fernstrom, M. H., & Kupfer, D. J. (1988) · Psychiatry Research · doi:10.1016/0165-1781(88)90120-5 · Cited by 77
Do Bupropion SR and Sertraline Differ in Their Effects on Anxiety in Depressed Patients?
Trivedi, M. H., Rush, A. J., Carmody, T. J., Donahue, R. M. J., Watson, C. B., Houser, T. L., & Metz, A. L. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n1005 · Cited by 75 · cited 1×
“Moreover, bupropion has demonstrated comparable efficacy when administered in conjunction with the SSRI sertraline in treating depression (and anxious symptoms of depression) even among patients with high levels of anxiety at baseline.(42,43) The distinctive neuropharmacologic properties of bupropion do, however, have…”
BackgroundDeBattista, C., Solvason, H. B., Poirier, J., Kendrick, E., & Loraas, E. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0706 · Cited by 75
Depue, R. A., Arbisi, P., Krauss, S., Iacono, W. G., Leon, A. C., Muir, R., & Allen, J. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810160056009 · Cited by 74
Dopamine Receptor Subtype Agonists and Feeding Behavior
Terry, P., Gilbert, D. B., & Cooper, S. J. (1995) · Obesity Research · doi:10.1002/j.1550-8528.1995.tb00221.x · Cited by 74 · cited 1×
“brain pathways have critical roles in the regulation of appetite, satiety, and feeding behavior.(97,98)”
BackgroundBupropion Treatment of Serotonin Reuptake Antidepressant-Associated Sexual Dysfunction
Labbate, L. A., Grimes, J. B., Hines, A., & Pollack, M. H. (1997) · Annals of Clinical Psychiatry · doi:10.1023/a:1022356427242 · Cited by 73
Ansseau, M., von Frenckell, R., Mertens, C., Wilde, J. D., Botte, L., Devoitille, J.-M., Evrard, J.-L., Nayer, A. D., Darimont, P., Dejaiffe, G., et al. (1989) · Psychopharmacology · doi:10.1007/bf00444686 · Cited by 72
Bupropion-Sustained Release as a Treatment for SSRI-Induced Sexual Side Effects
Gitlin, M. J., Suri, R., Altshuler, L. L., Zuckerbrow-Miller, J., & Fairbanks, L. A. (2002) · Journal of Sex & Marital Therapy · doi:10.1080/00926230252851870 · Cited by 68
Bupropion Treatment of Serotonin Reuptake Antidepressant-Associated Sexual Dysfunction
Labbate, L. A., Grimes, J. B., Hines, A., et al. (1997) · Annals of Clinical Psychiatry · doi:10.3109/10401239709147804 · Cited by 54
Tricyclic Antidepressants and Convulsions
Jick, H., Dinan, B. J., Hunter, J. R., Stergachis, A. S., Ronning, A., PERERA, D. R., Madsen, S., & Nudelman, P. M. (1983) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198306000-00008 · Cited by 50
Interaction of Reserpine, Serotonin, and Lysergic Acid Diethylamide in Brain
Shore, P. A., Silver, S. L., & Brodie, B. B. (1955) · Science · doi:10.1126/science.122.3163.284.b · Cited by 50
Effects of bupropion on body weight.
Harto-Truax, N., Stern, W. C., Miller, L. L., Tl, S., & Cato, A. E. (1983) · PubMed · Cited by 49
Seizures during tricyclic therapy
Lowry, M., & Dunner, F. J. (1980) · American Journal of Psychiatry · doi:10.1176/ajp.137.11.1461 · Cited by 45
Chronic imipramine treatment and weight gain
Fernstrom, M. H., Krowinski, R. L., & Kupfer, D. J. (1986) · Psychiatry Research · doi:10.1016/0165-1781(86)90074-0 · Cited by 37
CURRENT PERSPECTIVES ON THE PATHOPHYSIOLOGY OF SCHIZOPHRENIA, DEPRESSION, AND ANXIETY DISORDERS
Krystal, J. H., D’Souza, D. C., Sanacora, G., Goddard, A. W., & Charney, D. S. (2001) · Medical Clinics of North America · doi:10.1016/s0025-7125(05)70329-1 · Cited by 37 · cited 1×
“cause depression and modulate responses to antidepressants.(14,16,19) Several observations support an “upstream””
BackgroundDoes pretreatment anxiety predict response to either bupropion SR or sertraline?
Rush, A. J., Batey, S. R., Donahue, R. M. J., Ascher, J. A., Carmody, T. J., & Metz, A. L. (2001) · Journal of Affective Disorders · doi:10.1016/s0165-0327(00)00250-0 · Cited by 32 · cited 1×
“Moreover, bupropion has demonstrated comparable efficacy when administered in conjunction with the SSRI sertraline in treating depression (and anxious symptoms of depression) even among patients with high levels of anxiety at baseline.(42,43) The distinctive neuropharmacologic properties of bupropion do, however, have…”
BackgroundDopamine and circadian rhythms in seasonal affective disorder
Partonen, T. (1996) · Medical Hypotheses · doi:10.1016/s0306-9877(96)90079-1 · Cited by 17
Perlis, R. H., D, M. F. M., Nierenberg, A. A., Pollack, M. H., Falk, W. E., Kienke, A. S., & Rosenbaum, J. F. (2002) · Harvard Review of Psychiatry · doi:10.1080/10673220216211 · Cited by 17
Rowe, P. M. (1995) · Molecular Medicine Today · doi:10.1016/s1357-4310(95)90551-0 · Cited by 6
Perlis, R. H. (2002) · Harvard Review of Psychiatry · doi:10.1093/hrp/10.2.109 · Cited by 1
Research works printed but not linked: 27
- Ferris RM, Cooper BR. Mechanism of antidepressant activity of bupropion. J Clin Psychiatry Monograph. 1993;11(1):2–14. [PubMed] [Google Scholar]
- GlaxoSmithKline. data on file, Research Triangle Park, NC. 2002. [Google Scholar]
- Stahl SM. Essential Psychopharmacology. 2nd ed. New York, NY: Cambridge University Press. 2000 [Google Scholar]
- Remeron [package, insert]. West Orange, NJ: Organon. 2002. [Google Scholar]
- Serzone [package, insert]. Princeton, NJ: Bristol-Myers Squibb Company. 2002. [Google Scholar]
- Holden C. ed. Random samples: don't go off the Prozac. Science. 2003 301:760–761. [Google Scholar]
- Szabó Z, Àrgyelán M, and Kanyó B. et al. The effect of bupropion on the activity of dopamine transporter in depression: preliminary results [abstract]. Eur Neuropsychopharmacol. 2003 13(suppl 4):S210. [Google Scholar]
- American Psychiatric Association. Major Depressive Disorder: A Patient and Family Guide, 2001. Available at: www.psych.org. Accessed June 7, 2001. [Google Scholar]
- Geddes JR, Freemantle N, and Mason J. et al. SSRIs versus other anti-depressants for depressive disorder. Cochrane Database Syst Rev 2000(2):CD001851. [DOI] [PubMed] [Google Scholar]
- Thase ME, Haight BR, and Richard NE. et al. Remission rates following therapy with bupropion or SSRIs. Presented at the 156th annual meeting of the American Psychiatric Association. 17–22May2003 San Francisco, Calif. [Google Scholar]
- Boyer WF, Feighner JP. The combined use of fluoxetine and bupropion [poster]. Presented at the 146th annual meeting of the American Psychiatric Association. 22–27May1993 San Francisco, Calif. [Google Scholar]
- Ramasubbu R. Treatment of resistant depression by adding noradrenergic agents to lithium augmentation of SSRIs. Ann Pharmacother. 2002;36:634–640. doi: 10.1345/aph.10408. [DOI] [PubMed] [Google Scholar] · doi:10.1345/aph.10408 · Paper page
- Spier SA. Use of bupropion with SRIs and venlafaxine. Depress Anxiety. 1998;7:73–75. [PubMed] [Google Scholar]
- Yeghiya M, Danielyan A, and Khachatur G. et al. Augmentation of SSRIs with bupropion in treatment resistant depression in adolescents [abstract]. Presented at the 156th annual meeting of the American Psychiatric Association. 17–22May2003 San Francisco, Calif. [Google Scholar]
- DeBattista C, Solvason HB, and Fleming S. et al. A placebo-controlled, double-blind study of bupropion SR in the treatment of SSRI-induced sexual dysfunction [poster]. Presented at the 154th annual meeting of the American Psychiatric Association. 5–10May2001 New Orleans, La. [DOI] [PubMed] [Google Scholar]
- Solvason HB, DeBattista C, and Kendrick E. et al. Bupropion SR in the treatment of SSRI-induced sexual dysfunction [poster]. Presented at the 40th annual meeting of the New Clinical Drug Evaluation Unit Program (NCDEU). May 30–June 2, 2000 Boca Raton, Fla. [Google Scholar]
- Johnston JA, Schmidt G, and Ascher J. et al. Pharmacokinetic optimization of bupropion SR for smoking cessation. Drugs. 2002 62(suppl 2):11–24. [DOI] [PubMed] [Google Scholar]
- Hudziak JJ, Wilens TE, and Rosenthal NE. et al. The efficacy of extended-release bupropion in adult ADHD [poster]. Presented at the 42nd annual meeting of the American College of Neuropsychopharmacology. 7–11December2003 San Juan, Puerto Rico. [Google Scholar]
- Rosenthal NE, Modell JG, and Harriett A. et al. Wellbutrin XL for the prevention of seasonal depressive episodes [poster]. Presented at the 42nd annual meeting of the American College of Neuropsychopharmacology. 7–11December2003 San Juan, Puerto Rico. [Google Scholar]
- Clayton AH, West SG. The effects of antidepressants on human sexuality. Primary Psychiatry. 2003;10:62–70. [Google Scholar]
- Westlund R, Haight BR, and Harriett A. et al. Effect on body weight of bupropion in patients with major depression [poster]. Presented at the 16th Annual US Psychiatric & Mental Health Congress. 6–9November2003 Orlando, Fla. [Google Scholar]
- Celexa [package, insert]. St Louis, Mo: Forest Laboratories. 2002. [Google Scholar]
- Prozac [package, insert]. Indianapolis, Ind: Eli Lilly and Company. 2002. [Google Scholar]
- Paxil [package, insert]. Research Triangle Park, NC: GlaxoSmithKline. 2002. [Google Scholar]
- Zoloft [package, insert]. New York, NY: Pfizer Inc. 2002. [Google Scholar]
- Effexor [package, insert]. Philadelphia, Pa: Wyeth. 2002. [Google Scholar]
- Wellbutrin [package, insert]. Research Triangle Park, NC: GlaxoSmithKline. 2002. [Google Scholar]
Cited by
Reconsidering anhedonia in depression: Lessons from translational neuroscience
Treadway, M. T., & Zald, D. H. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.06.006 · Cited by 1,579
“It is well established that bupropion has little direct effect on 5HT function (Stahl et al., 2004).”
BackgroundMalhi, G. S., Bassett, D., Boyce, P., Bryant, R., Fitzgerald, P. B., Fritz, K., Hopwood, M., Lyndon, B., Mulder, R., Murray, G., et al. (2015) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867415617657 · Cited by 842
“However, if the patient was nonresponsive to the initial SSRI, switching out of class to a SNRI (i.e., venlafaxine), NDRI or TCA, is recommended (Ruhé et al., 2006b; Rush et al., 2006).”
BackgroundA brief history of the development of antidepressant drugs: From monoamines to glutamate.
Hillhouse, T. M., & Porter, J. H. (2015) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0038550 · Cited by 605
“Bupropion IR requires three daily doses; thus, to reduce daily dosing regimens, the sustained-release (SR) and extended-release (XL) were developed and approved by the FDA in 1996 and 2003, respectively (Fava et al., 2005; Stahl et al., 2004).”
BackgroundInfluentialWadden, T. A., Foreyt, J. P., Foster, G. D., Hill, J. O., Klein, S., O'Neil, P. M., Perri, M. G., Pi‐Sunyer, F. X., Rock, C. L., Erickson, J. S., et al. (2011) · Obesity · doi:10.1038/oby.2010.147 · Cited by 558
A clinical perspective of obesity, metabolic syndrome and cardiovascular disease
Han, T. S., & Lean, M. E. (2016) · JRSM Cardiovascular Disease · doi:10.1177/2048004016633371 · Cited by 500
Metadata
- Authors
- Stahl, S. M., Pradko, J., Haight, B. R., Modell, J. G., Rockett, C. B., & Learned-Coughlin, S.
- Affiliations
- University of California San Diego (US)
- St. John Hospital & Medical Center (US)
- Corresponding author
- Modell, Jack G.
- ORCID
- Stahl, Stephen M.
- Venue
- The Primary Care Companion For CNS Disorders
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2004-08-13
- Volume
- 6
- Issue
- 4
- Pages
- 159-166
- ISSN
- 2155-7772 (ISSN-L)
- 2155-7780
- PMC
- PMC514842
- OpenAlex
- W2046809238
- Cited by
- 495
- References
- 92
- Citations by year
- 2026: 14 · 2025: 28 · 2024: 31 · 2023: 33 · 2022: 35 · 2021: 27 · 2020: 27 · 2019: 19 · 2018: 36 · 2017: 25 · 2016: 29 · 2015: 23 · 2014: 19 · 2013: 20 · 2012: 15
- FWCI
- 8.57
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Primary Care Companion For CNS Disorders (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- bupropion, norepinephrine reuptake inhibition, dopamine uptake inhibition, antidepressant mechanism, antidepressant efficacy, antidepressant tolerability, sexual dysfunction, weight gain, sedation, serotonergic effects
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.